VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q89863701  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235938.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q89863701‏
024 ‎‡a  0000-0002-1926-0043‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q89863701‏
100 0 ‎‡a  Anna Bal-Price‏ ‎‡c  researcher‏ ‎‡9  en‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  Anna Bal-Price‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A human pluripotent carcinoma stem cell-based model for in vitro developmental neurotoxicity testing: effects of methylmercury, lead and aluminum evaluated by gene expression studies‏
670 ‎‡a  Author's A multi-laboratory evaluation of microelectrode array-based measurements of neural network activity for acute neurotoxicity testing.‏
670 ‎‡a  Author's Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems‏
670 ‎‡a  Author's Advancing human health risk assessment‏
670 ‎‡a  Author's Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity‏
670 ‎‡a  Author's Alternative‏
670 ‎‡a  Author's Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.‏
670 ‎‡a  Author's An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.‏
670 ‎‡a  Author's An analysis of the limitations and uncertainties of in vivo developmental neurotoxicity testing and assessment to identify the potential for alternative approaches‏
670 ‎‡a  Author's Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept‏
670 ‎‡a  Author's Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis‏
670 ‎‡a  Author's Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes‏
670 ‎‡a  Author's Corrigendum to Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity‏
670 ‎‡a  Author's Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity‏
670 ‎‡a  Author's Development and analysis of an adverse outcome pathway network for human neurotoxicity‏
670 ‎‡a  Author's Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity‏
670 ‎‡a  Author's Development of the Adverse Outcome Pathway‏
670 ‎‡a  Author's Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children‏
670 ‎‡a  Author's Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals.‏
670 ‎‡a  Author's Early life exposure to air pollution particulate matter‏
670 ‎‡a  Author's Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.‏
670 ‎‡a  Author's Editorial: Developmental neurotoxicity‏
670 ‎‡a  Author's Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models‏
670 ‎‡a  Author's Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells‏
670 ‎‡a  Author's Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells‏
670 ‎‡a  Author's Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides‏
670 ‎‡a  Author's Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells‏
670 ‎‡a  Author's Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells (NT2) caused by exposure to organophosphorus compounds paraoxon and mipafox‏
670 ‎‡a  Author's Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) - Draft for stakeholder discussion and call for action‏
670 ‎‡a  Author's Good Cell Culture Practice for stem cells and stem-cell-derived models.‏
670 ‎‡a  Author's Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice‏
670 ‎‡a  Author's Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide‏
670 ‎‡a  Author's Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation‏
670 ‎‡a  Author's Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria‏
670 ‎‡a  Author's Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death‏
670 ‎‡a  Author's Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells‏
670 ‎‡a  Author's International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing‏
670 ‎‡a  Author's International STakeholder NETwork‏
670 ‎‡a  Author's International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes‏
670 ‎‡a  Author's International STakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes‏
670 ‎‡a  Author's Investigating cell type specific mechanisms contributing to acute oral toxicity‏
670 ‎‡a  Author's Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia†‏
670 ‎‡a  Author's Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake.‏
670 ‎‡a  Author's Message from the Editor-in-Chief‏
670 ‎‡a  Author's miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing‏
670 ‎‡a  Author's mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach‏
670 ‎‡a  Author's Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes‏
670 ‎‡a  Author's Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion‏
670 ‎‡a  Author's Nrf2 pathway activation upon rotenone treatment in human iPSC-derived neural stem cells undergoing differentiation towards neurons and astrocytes‏
670 ‎‡a  Author's OECD/EFSA workshop on developmental neurotoxicity‏
670 ‎‡a  Author's OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.‏
670 ‎‡a  Author's Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop.‏
670 ‎‡a  Author's Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing‏
670 ‎‡a  Author's Putative adverse outcome pathways relevant to neurotoxicity‏
670 ‎‡a  Author's Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity‏
670 ‎‡a  Author's Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use.‏
670 ‎‡a  Author's Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways‏
670 ‎‡a  Author's Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production‏
670 ‎‡a  Author's Strategies to improve the regulatory assessment of developmental neurotoxicity‏
670 ‎‡a  Author's Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods‏
670 ‎‡a  Author's The value of alternative testing for neurotoxicity in the context of regulatory needs‏
670 ‎‡a  Author's Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies‏
909 ‎‡a  (orcid) 0000000219260043‏ ‎‡9  1‏
912 ‎‡a  alternative‏ ‎‡A  Alternative‏ ‎‡9  1‏
919 ‎‡a  putativeadverseoutcomepathwaysrelevanttoneurotoxicity‏ ‎‡A  Putative adverse outcome pathways relevant to neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  workgroupreportincorporatinginvitroalternativemethodsfordevelopmentalneurotoxicityintointernationalhazardandriskassessmentstrategies‏ ‎‡A  Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies‏ ‎‡9  1‏
919 ‎‡a  valueofalternativetestingforneurotoxicityinthecontextofregulatoryneeds‏ ‎‡A  The value of alternative testing for neurotoxicity in the context of regulatory needs‏ ‎‡9  1‏
919 ‎‡a  strategiestoimprovetheregulatoryassessmentofdevelopmentalneurotoxicitydntusinginvitromethods‏ ‎‡A  Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods‏ ‎‡9  1‏
919 ‎‡a  strategiestoimprovetheregulatoryassessmentofdevelopmentalneurotoxicity‏ ‎‡A  Strategies to improve the regulatory assessment of developmental neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  stimulationofthenadphoxidaseinactivatedratmicrogliaremovesnitricoxidebutinducesperoxynitriteproduction‏ ‎‡A  Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production‏ ‎‡9  1‏
919 ‎‡a  representingtheprocessofinflammationaskeyeventsinadverseoutcomepathways‏ ‎‡A  Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways‏ ‎‡9  1‏
919 ‎‡a  referencecompoundsforalternativetestmethodstoindicatedevelopmentalneurotoxicitydntpotentialofchemicalsexamplelistsandcriteriafortheirselectionanduse‏ ‎‡A  Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use.‏ ‎‡9  1‏
919 ‎‡a  recommendationontestreadinesscriteriafornewapproachmethodsintoxicologyexemplifiedfordevelopmentalneurotoxicity‏ ‎‡A  Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  humanpluripotentcarcinomastemcellbasedmodelforinvitrodevelopmentalneurotoxicitytestingeffectsofmethylmercuryleadandaluminumevaluatedbygeneexpressionstudies‏ ‎‡A  A human pluripotent carcinoma stem cell-based model for in vitro developmental neurotoxicity testing: effects of methylmercury, lead and aluminum evaluated by gene expression studies‏ ‎‡9  1‏
919 ‎‡a  multilaboratoryevaluationofmicroelectrodearraybasedmeasurementsofneuralnetworkactivityforacuteneurotoxicitytesting‏ ‎‡A  A multi-laboratory evaluation of microelectrode array-based measurements of neural network activity for acute neurotoxicity testing.‏ ‎‡9  1‏
919 ‎‡a  advancedgoodcellculturepracticeforhumanprimarystemcellderivedandorganoidmodelsaswellasmicrophysiologicalsystems‏ ‎‡A  Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems‏ ‎‡9  1‏
919 ‎‡a  advancinghumanhealthriskassessment‏ ‎‡A  Advancing human health risk assessment‏ ‎‡9  1‏
919 ‎‡a  adverseoutcomepathwaysapplicationtoenhancemechanisticunderstandingofneurotoxicity‏ ‎‡A  Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  alternativenonanimalmethodsforcosmeticstestingcurrentstatusandfutureprospects‏ ‎‡A  Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.‏ ‎‡9  1‏
919 ‎‡a  adverseoutcomepathwayforparkinsonianmotordeficitsassociatedwithmitochondrialcomplex1inhibition‏ ‎‡A  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.‏ ‎‡9  1‏
919 ‎‡a  analysisofthelimitationsanduncertaintiesofinvivodevelopmentalneurotoxicitytestingandassessmenttoidentifythepotentialforalternativeapproaches‏ ‎‡A  An analysis of the limitations and uncertainties of in vivo developmental neurotoxicity testing and assessment to identify the potential for alternative approaches‏ ‎‡9  1‏
919 ‎‡a  assessmentofdevelopmentalneurotoxicityinducedbychemicalmixturesusinganadverseoutcomepathwayconcept‏ ‎‡A  Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept‏ ‎‡9  1‏
919 ‎‡a  brainonachipmodelenablesanalysisofhumanneuronaldifferentiationandchemotaxis‏ ‎‡A  Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis‏ ‎‡9  1‏
919 ‎‡a  consensusstatementontheneedforinnovationtransitionandimplementationofdevelopmentalneurotoxicitydnttestingforregulatorypurposes‏ ‎‡A  Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes‏ ‎‡9  1‏
919 ‎‡a  corrigendumtorecommendationontestreadinesscriteriafornewapproachmethodsintoxicologyexemplifiedfordevelopmentalneurotoxicity‏ ‎‡A  Corrigendum to Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  developingandapplyingtheadverseoutcomepathwayconceptforunderstandingandpredictingneurotoxicity‏ ‎‡A  Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  developmentandanalysisofanadverseoutcomepathwaynetworkforhumanneurotoxicity‏ ‎‡A  Development and analysis of an adverse outcome pathway network for human neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  developmentofamechanisticallybasedgeneticallyengineeredpc12cellsystemtodetectp53mediatedcytotoxicity‏ ‎‡A  Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity‏ ‎‡9  1‏
919 ‎‡a  developmentoftheadverseoutcomepathway‏ ‎‡A  Development of the Adverse Outcome Pathway‏ ‎‡9  1‏
919 ‎‡a  developmentoftheadverseoutcomepathwayaopchronicbindingofantagonisttonmethyl500aspartatereceptorsnmdarsduringbraindevelopmentinducesimpairmentoflearningandmemoryabilitiesofchildren‏ ‎‡A  Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children‏ ‎‡9  1‏
919 ‎‡a  developmentalneurotoxicitytestingrecommendationsfordevelopingalternativemethodsforthescreeningandprioritizationofchemicals‏ ‎‡A  Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals.‏ ‎‡9  1‏
919 ‎‡a  earlylifeexposuretoairpollutionparticulatematter‏ ‎‡A  Early life exposure to air pollution particulate matter‏ ‎‡9  1‏
919 ‎‡a  earlylifeexposuretoairpollutionparticulatematterpmasriskfactorforattentiondeficithyperactivitydisorderadhdneedfornovelstrategiesformechanismsandcausalities‏ ‎‡A  Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.‏ ‎‡9  1‏
919 ‎‡a  editorialdevelopmentalneurotoxicity‏ ‎‡A  Editorial: Developmental neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  evaluationofdruginducedneurotoxicitybasedonmetabolomicsproteomicsandelectricalactivitymeasurementsincomplementarycnsinvitromodels‏ ‎‡A  Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models‏ ‎‡9  1‏
919 ‎‡a  evaluationoftherotenoneinducedactivationofthenrf2pathwayinaneuronalmodelderivedfromhumaninducedpluripotentstemcells‏ ‎‡A  Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells‏ ‎‡9  1‏
919 ‎‡a  geneexpressionasasensitiveendpointtoevaluatecelldifferentiationandmaturationofthedevelopingcentralnervoussysteminprimaryculturesofratcerebellargranulecells‏ ‎‡A  Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells‏ ‎‡9  1‏
919 ‎‡a  geneexpressionasasensitiveendpointtoevaluatecelldifferentiationandmaturationofthedevelopingcentralnervoussysteminprimaryculturesofratcerebellargranulecellscgcsexposedtopesticides‏ ‎‡A  Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides‏ ‎‡9  1‏
919 ‎‡a  genomicandphenotypicalterationsoftheneuronallikecellsderivedfromhumanembryonalcarcinomastemcells‏ ‎‡A  Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells‏ ‎‡9  1‏
919 ‎‡a  genomicandphenotypicalterationsoftheneuronallikecellsderivedfromhumanembryonalcarcinomastemcellsnt2causedbyexposuretoorganophosphoruscompoundsparaoxonandmipafox‏ ‎‡A  Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells (NT2) caused by exposure to organophosphorus compounds paraoxon and mipafox‏ ‎‡9  1‏
919 ‎‡a  goodcellandtissueculturepractice20gccp20draftforstakeholderdiscussionandcallforaction‏ ‎‡A  Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) - Draft for stakeholder discussion and call for action‏ ‎‡9  1‏
919 ‎‡a  goodcellculturepracticeforstemcellsandstemcellderivedmodels‏ ‎‡A  Good Cell Culture Practice for stem cells and stem-cell-derived models.‏ ‎‡9  1‏
919 ‎‡a  guidanceongoodcellculturepracticeareportofthe2ecvamtaskforceongoodcellculturepractice‏ ‎‡A  Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice‏ ‎‡9  1‏
919 ‎‡a  highlypurifiedlipoteichoicacidinducedproinflammatorysignallinginprimarycultureofratmicrogliathroughtolllikereceptor2selectivepotentiationofnitricoxideproductionbymuramyldipeptide‏ ‎‡A  Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide‏ ‎‡9  1‏
919 ‎‡a  inflammatoryneurodegenerationinducedbylipoteichoicacidfromstaphylococcusaureusismediatedbygliaactivationnitrosativeandoxidativestressandcaspaseactivation‏ ‎‡A  Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation‏ ‎‡9  1‏
919 ‎‡a  inflammatoryneurodegenerationmediatedbynitricoxideglutamateandmitochondria‏ ‎‡A  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria‏ ‎‡9  1‏
919 ‎‡a  inhibitionofmicroglialphagocytosisissufficienttopreventinflammatoryneuronaldeath‏ ‎‡A  Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death‏ ‎‡9  1‏
919 ‎‡a  integratingbiokineticsandinvitrostudiestoevaluatedevelopmentalneurotoxicityinducedbychlorpyrifosinhumanipscderivedneuralstemcellsundergoingdifferentiationtowardsneuronalandglialcells‏ ‎‡A  Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells‏ ‎‡9  1‏
919 ‎‡a  internationalregulatoryandscientificeffortforimproveddevelopmentalneurotoxicitytesting‏ ‎‡A  International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing‏ ‎‡9  1‏
919 ‎‡a  internationalstakeholdernetwork‏ ‎‡A  International STakeholder NETwork‏ ‎‡9  1‏
919 ‎‡a  internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes‏ ‎‡A  International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes‏ ‎‡9  1‏
919 ‎‡a  internationalstakeholdernetworkistnetforcreatingadevelopmentalneurotoxicitytestingdntroadmapforregulatorypurposes‏ ‎‡A  International STakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes‏ ‎‡9  1‏
919 ‎‡a  investigatingcelltypespecificmechanismscontributingtoacuteoraltoxicity‏ ‎‡A  Investigating cell type specific mechanisms contributing to acute oral toxicity‏ ‎‡9  1‏
919 ‎‡a  investigationintoexperimentaltoxicologicalpropertiesofplantprotectionproductshavingapotentiallinktoparkinsonsdiseaseandchildhoodleukaemia‏ ‎‡A  Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia†‏ ‎‡9  1‏
919 ‎‡a  mechanismsoftoxicityinducedbysio2nanoparticlesofinvitrohumanalveolarbarriereffectsoncytokineproductionoxidativestressinductionsurfactantproteinsamrnaexpressionandnanoparticlesuptake‏ ‎‡A  Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake.‏ ‎‡9  1‏
919 ‎‡a  messagefromtheeditorinchief‏ ‎‡A  Message from the Editor-in-Chief‏ ‎‡9  1‏
919 ‎‡a  mirnaexpressionprofilinginahumanstemcellbasedmodelasatoolfordevelopmentalneurotoxicitytesting‏ ‎‡A  miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing‏ ‎‡9  1‏
919 ‎‡a  mrnaexpressionisarelevanttooltoidentifydevelopmentalneurotoxicantsusinganinvitroapproach‏ ‎‡A  mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach‏ ‎‡9  1‏
919 ‎‡a  nitricoxideinducesrapidcalciumdependentreleaseofvesicularglutamateandatpfromculturedratastrocytes‏ ‎‡A  Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes‏ ‎‡9  1‏
919 ‎‡a  nitricoxidestimulatespc12cellproliferationviacgmpandinhibitsathigherconcentrationsmainlyviaenergydepletion‏ ‎‡A  Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion‏ ‎‡9  1‏
919 ‎‡a  nrf2pathwayactivationuponrotenonetreatmentinhumanipscderivedneuralstemcellsundergoingdifferentiationtowardsneuronsandastrocytes‏ ‎‡A  Nrf2 pathway activation upon rotenone treatment in human iPSC-derived neural stem cells undergoing differentiation towards neurons and astrocytes‏ ‎‡9  1‏
919 ‎‡a  oecdefsaworkshopondevelopmentalneurotoxicity‏ ‎‡A  OECD/EFSA workshop on developmental neurotoxicity‏ ‎‡9  1‏
919 ‎‡a  oecdefsaworkshopondevelopmentalneurotoxicitydnttheuseofnonanimaltestmethodsforregulatorypurposes‏ ‎‡A  OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.‏ ‎‡9  1‏
919 ‎‡a  overcomingbarrierstovalidationofnonanimalpartialreplacementmethodsintegratedtestingstrategiesthereportofanepaaecvamworkshop‏ ‎‡A  Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop.‏ ‎‡9  1‏
919 ‎‡a  protocolforthedifferentiationofhumaninducedpluripotentstemcellsintomixedculturesofneuronsandgliaforneurotoxicitytesting‏ ‎‡A  Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing‏ ‎‡9  1‏
943 ‎‡a  201x‏ ‎‡A  2010‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000024238604‏
996 ‎‡2  J9U|987007388575205171‏
996 ‎‡2  LC|n 2001022114‏
996 ‎‡2  BIBSYS|2131256‏
996 ‎‡2  ISNI|0000000455675929‏
996 ‎‡2  J9U|987007414717405171‏
996 ‎‡2  LC|n 86806983‏
996 ‎‡2  J9U|987007405520205171‏
996 ‎‡2  ISNI|0000000023632562‏
996 ‎‡2  LC|n 84231363‏
996 ‎‡2  NII|DA08123106‏
996 ‎‡2  LC|n 2021181743‏
996 ‎‡2  DNB|1329538242‏
996 ‎‡2  LC|n 86108650‏
996 ‎‡2  SUDOC|270390219‏
996 ‎‡2  SUDOC|203354613‏
996 ‎‡2  LC|nb2007025362‏
996 ‎‡2  LC|n 2020018371‏
996 ‎‡2  BNE|XX1052510‏
996 ‎‡2  ISNI|0000000496410433‏
996 ‎‡2  NUKAT|n 2011063995‏
996 ‎‡2  LIH|LNB:DJ_e__y_;=B8‏
996 ‎‡2  LC|nb2009005053‏
996 ‎‡2  LC|n 87135583‏
996 ‎‡2  SUDOC|033494673‏
996 ‎‡2  SZ|123157552‏
996 ‎‡2  LC|n 90698930‏
996 ‎‡2  BNF|12278899‏
996 ‎‡2  ISNI|0000000053479095‏
996 ‎‡2  N6I|vtls002016362‏
996 ‎‡2  LC|n 91072650‏
996 ‎‡2  SUDOC|169822532‏
996 ‎‡2  LC|nb2007012488‏
996 ‎‡2  BIBSYS|90524487‏
996 ‎‡2  LC|n 93099946‏
996 ‎‡2  SUDOC|230184561‏
996 ‎‡2  CAOONL|ncf10239188‏
996 ‎‡2  J9U|987007330805205171‏
996 ‎‡2  J9U|987007432096905171‏
996 ‎‡2  LC|no2019036117‏
996 ‎‡2  NII|DA01188599‏
996 ‎‡2  J9U|987007343239605171‏
996 ‎‡2  ISNI|0000000074451024‏
996 ‎‡2  ISNI|0000000073805441‏
996 ‎‡2  ISNI|0000000028677508‏
996 ‎‡2  N6I|vtls002452627‏
996 ‎‡2  CAOONL|ncf10058782‏
996 ‎‡2  LC|n 89120460‏
996 ‎‡2  SUDOC|225582589‏
996 ‎‡2  RERO|A003711589‏
996 ‎‡2  LC|nr 97008141‏
996 ‎‡2  LC|no2010033525‏
996 ‎‡2  LC|no2015034653‏
996 ‎‡2  CAOONL|ncf10514178‏
996 ‎‡2  LC|nr 93031612‏
996 ‎‡2  J9U|987007457221505171‏
996 ‎‡2  ISNI|000000002767660X‏
996 ‎‡2  ISNI|0000000034394424‏
996 ‎‡2  BIBSYS|90055338‏
996 ‎‡2  NUKAT|n 2010075635‏
996 ‎‡2  ISNI|0000000500193153‏
996 ‎‡2  LC|no2004026507‏
996 ‎‡2  LC|n 83234856‏
996 ‎‡2  ISNI|0000000460194388‏
996 ‎‡2  ISNI|0000000040758001‏
996 ‎‡2  SUDOC|161992234‏
996 ‎‡2  NTA|068495595‏
996 ‎‡2  LC|no2015009146‏
996 ‎‡2  J9U|987007462287505171‏
996 ‎‡2  ISNI|0000000029020540‏
996 ‎‡2  LC|n 83223455‏
996 ‎‡2  ISNI|0000000077544146‏
996 ‎‡2  ISNI|0000000054983197‏
996 ‎‡2  LC|n 85031463‏
996 ‎‡2  LC|n 2019244535‏
996 ‎‡2  BLBNB|000591511‏
996 ‎‡2  RERO|A003711667‏
996 ‎‡2  RERO|A003711666‏
996 ‎‡2  RERO|A003711664‏
996 ‎‡2  BNF|17120411‏
996 ‎‡2  J9U|987007266766505171‏
996 ‎‡2  NTA|322490103‏
996 ‎‡2  ISNI|0000000035553730‏
996 ‎‡2  NUKAT|n 01015150‏
996 ‎‡2  LC|n 2004103360‏
996 ‎‡2  NKC|mzk2018989032‏
996 ‎‡2  LC|n 86135907‏
996 ‎‡2  J9U|987007418902305171‏
996 ‎‡2  LC|n 50020528‏
996 ‎‡2  ISNI|0000000048069761‏
996 ‎‡2  BIBSYS|90180591‏
996 ‎‡2  ISNI|0000000030675069‏
996 ‎‡2  SUDOC|267838441‏
996 ‎‡2  LC|n 84080789‏
996 ‎‡2  ISNI|0000000028105737‏
996 ‎‡2  LC|n 93070870‏
996 ‎‡2  LC|n 85031949‏
996 ‎‡2  BLBNB|000239505‏
996 ‎‡2  BIBSYS|6039643‏
996 ‎‡2  CAOONL|ncf10109026‏
996 ‎‡2  LC|n 77005813‏
996 ‎‡2  J9U|987010649954605171‏
996 ‎‡2  LC|n 85112174‏
996 ‎‡2  BNF|16561275‏
996 ‎‡2  RERO|A011687708‏
996 ‎‡2  LC|nr2006012116‏
996 ‎‡2  DNB|123157552‏
996 ‎‡2  NUKAT|n 2021084351‏
996 ‎‡2  NTA|238490602‏
996 ‎‡2  LC|no 91011838‏
996 ‎‡2  BIBSYS|13022415‏
996 ‎‡2  LC|no2019036534‏
996 ‎‡2  LC|nb2011009113‏
996 ‎‡2  LC|nr 96023630‏
996 ‎‡2  ISNI|000000007653160X‏
996 ‎‡2  LC|nr2006008602‏
996 ‎‡2  ISNI|0000000031560933‏
996 ‎‡2  LC|nb2008018814‏
996 ‎‡2  ISNI|0000000118794572‏
996 ‎‡2  NTA|151539294‏
996 ‎‡2  LC|n 79047890‏
996 ‎‡2  LC|no2014044158‏
996 ‎‡2  ISNI|0000000433153070‏
996 ‎‡2  ISNI|000000006332568X‏
996 ‎‡2  ISNI|0000000117371068‏
996 ‎‡2  LC|nb2011011874‏
996 ‎‡2  LC|no2020041985‏
996 ‎‡2  ISNI|0000000110781793‏
996 ‎‡2  NSK|000423288‏
996 ‎‡2  PLWABN|9813311335105606‏
996 ‎‡2  ISNI|0000000050095889‏
996 ‎‡2  LC|n 81065858‏
996 ‎‡2  LC|n 99047173‏
996 ‎‡2  SUDOC|098741004‏
996 ‎‡2  ISNI|0000000074219065‏
996 ‎‡2  PLWABN|9810548137005606‏
996 ‎‡2  NTA|074433679‏
996 ‎‡2  ISNI|0000000026394037‏
996 ‎‡2  LC|no 98033611‏
996 ‎‡2  LC|n 2019026585‏
996 ‎‡2  LC|n 2018186490‏
996 ‎‡2  LC|n 83187976‏
996 ‎‡2  DNB|1157902073‏
996 ‎‡2  BIBSYS|6085743‏
996 ‎‡2  J9U|987007362123105171‏
996 ‎‡2  LC|nr2001049074‏
996 ‎‡2  ISNI|0000000027464025‏
996 ‎‡2  ISNI|0000000510842508‏
996 ‎‡2  ISNI|0000000029837024‏
996 ‎‡2  ISNI|0000000054753594‏
996 ‎‡2  BNF|12437040‏
996 ‎‡2  ISNI|0000000028520957‏
996 ‎‡2  BIBSYS|90771880‏
996 ‎‡2  J9U|987007391806505171‏
996 ‎‡2  ISNI|0000000490287729‏
996 ‎‡2  NII|DA03066253‏
996 ‎‡2  LC|no2022072142‏
996 ‎‡2  LC|n 2018186006‏
996 ‎‡2  SUDOC|151820562‏
996 ‎‡2  ISNI|0000000079293926‏
996 ‎‡2  NUKAT|n 2016171869‏
996 ‎‡2  SUDOC|031606660‏
996 ‎‡2  NTA|090592522‏
996 ‎‡2  NUKAT|n 2016136145‏
996 ‎‡2  CAOONL|ncf11194646‏
996 ‎‡2  J9U|987012747981005171‏
996 ‎‡2  CAOONL|ncf11259654‏
996 ‎‡2  J9U|987007280762605171‏
996 ‎‡2  NUKAT|n 2006093144‏
996 ‎‡2  ISNI|0000000035080195‏
996 ‎‡2  ISNI|0000000369539461‏
996 ‎‡2  BIBSYS|98018691‏
996 ‎‡2  DNB|1292609575‏
996 ‎‡2  PLWABN|9813274201505606‏
996 ‎‡2  LC|n 91030195‏
996 ‎‡2  SIMACOB|320607331‏
996 ‎‡2  ISNI|0000000119704241‏
996 ‎‡2  CAOONL|ncf10458908‏
996 ‎‡2  LC|n 2005013631‏
996 ‎‡2  W2Z|1634281493355‏
996 ‎‡2  LC|no2019048471‏
996 ‎‡2  SUDOC|27118440X‏
996 ‎‡2  LC|n 92055833‏
996 ‎‡2  BIBSYS|90507015‏
996 ‎‡2  SUDOC|033510512‏
996 ‎‡2  BIBSYS|90726596‏
996 ‎‡2  CAOONL|ncf10341924‏
996 ‎‡2  BNF|12435575‏
996 ‎‡2  BIBSYS|14052459‏
996 ‎‡2  LC|nr2003022518‏
996 ‎‡2  NUKAT|n 00022984‏
996 ‎‡2  BIBSYS|14046615‏
996 ‎‡2  BIBSYS|1634281493355‏
996 ‎‡2  RERO|A023944280‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏